Advertisement
Advertisement
TNDM
Tandem Diabetes Care, Inc.
19.17
USDSponsored
+0.23
+1.21%
Feb 06, 15:59 UTC -5
Closed
After-Market
19.18
+0.01
+0.03%
TNDM Earnings Reports
Positive Surprise Ratio
TNDM beat 20 of 40 last estimates.
50%
Next Report
Date of Next Report
Feb 19, 2026
Estimate for Q4 25 (Revenue/ EPS)
$282.57M
/-$0.09
Implied change from Q3 25 (Revenue/ EPS)
+13.37%
/-70.97%
Implied change from Q4 24 (Revenue/ EPS)
-0.03%
/-1000.00%
Tandem Diabetes Care, Inc. earnings per share and revenue
On Nov 06, 2025, TNDM reported earnings of -0.31 USD per share (EPS) for Q3 25, beating the estimate of -0.32 USD, resulting in a 3.19% surprise. Revenue reached 249.25 million, compared to an expected 241.70 million, with a 3.12% difference. The market reacted with a +21.98% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 25 analysts forecast an EPS of -0.09 USD, with revenue projected to reach 282.57 million USD, implying an decrease of -70.97% EPS, and increase of 13.37% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Mesa Laboratories Inc
Report Date
Feb 03, 2026 For Q3 26
Estimate
$0.28
Actual
$3.07
Surprise
+987.88%
Accuray Incorporated
Report Date
Feb 04, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+1.96%
Thermo Fisher Scientific, Inc.
Report Date
Jan 29, 2026 For Q4 25
Estimate
$6.51
Actual
$6.57
Surprise
+0.91%
Idexx Laboratories Inc
Report Date
Feb 02, 2026 For Q4 25
Estimate
$2.98
Actual
$3.08
Surprise
+3.12%
IQVIA Holdings Inc.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$3.43
Actual
$3.42
Surprise
-0.34%
Mettler-Toledo International
Report Date
Feb 05, 2026 For Q4 25
Estimate
$12.92
Actual
$13.36
Surprise
+3.34%
STERIS plc
Report Date
Feb 04, 2026 For Q3 26
Estimate
$2.55
Actual
$2.52
Surprise
-0.99%
Hologic Inc
Report Date
Jan 29, 2026 For Q1 26
Estimate
$1.11
Actual
$1.04
Surprise
-6.45%
FAQ
What were Tandem Diabetes Care, Inc.'s earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Tandem Diabetes Care, Inc. reported EPS of -$0.31, beating estimates by 3.19%, and revenue of $249.25M, 3.12% above expectations.
How did the market react to Tandem Diabetes Care, Inc.'s Q3 2025 earnings?
The stock price moved up 21.98%, changed from $13.33 before the earnings release to $16.26 the day after.
When is Tandem Diabetes Care, Inc. expected to report next?
The next earning report is scheduled for Feb 19, 2026.
What are the forecasts for Tandem Diabetes Care, Inc.'s next earnings report?
Based on 25
analysts, Tandem Diabetes Care, Inc. is expected to report EPS of -$0.09 and revenue of $282.57M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement